Previous research has demonstrated the prognostic value of CD8+ T cells, and this study identified a regulatory effect of YARS1 on CD8+ T cells, suggesting that YARS1 may affect the prognosis of patients with bladder cancer by influencing CD8+ T cells. This evidence concerns the gene CD8A and urinary bladder carcinoma.